NASDAQ:RYTM Rhythm Pharmaceuticals (RYTM) Stock Forecast, Price & News $23.31 +0.08 (+0.34%) (As of 09/22/2023 ET) Add Compare Share Share Today's Range$22.86▼$23.7950-Day Range$16.78▼$27.8052-Week Range$15.50▼$34.99Volume522,616 shsAverage Volume554,615 shsMarket Capitalization$1.33 billionP/E RatioN/ADividend YieldN/APrice Target$37.17 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Rhythm Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside59.4% Upside$37.17 Price TargetShort InterestBearish21.34% of Float Sold ShortDividend StrengthN/ASustainability-1.80Upright™ Environmental ScoreNews Sentiment0.80Based on 8 Articles This WeekInsider TradingSelling Shares$503,100 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.24) to ($2.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.03 out of 5 starsMedical Sector554th out of 968 stocksPharmaceutical Preparations Industry248th out of 441 stocks 3.4 Analyst's Opinion Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $37.17, Rhythm Pharmaceuticals has a forecasted upside of 59.4% from its current price of $23.31.Amount of Analyst CoverageRhythm Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted21.34% of the float of Rhythm Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 13.3, which indicates bearish sentiment.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently decreased by 2.83%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRhythm Pharmaceuticals has received a 63.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Anti-obesity medication (A08)", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Rhythm Pharmaceuticals is -1.80. Previous Next 2.7 News and Social Media Coverage News SentimentRhythm Pharmaceuticals has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Rhythm Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for RYTM on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $503,100.00 in company stock.Percentage Held by InsidersOnly 4.70% of the stock of Rhythm Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($3.24) to ($2.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -7.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -7.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhythm Pharmaceuticals has a P/B Ratio of 4.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Rhythm Pharmaceuticals (NASDAQ:RYTM) StockRhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Read More RYTM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RYTM Stock News HeadlinesSeptember 22, 2023 | finance.yahoo.comRhythm Pharmaceuticals Presents New Data at ESPE 2023September 21, 2023 | msn.com"Rhythm Bath" aims to help make performing arts more accessible to families with disabilitiesSeptember 24, 2023 | Behind the Markets (Ad)AI Creates New Cancer Drug - In Just 30 Days!On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...September 20, 2023 | americanbankingnews.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 19, 2023 | msn.comOwensboro to host free Rhythm and Blues concertSeptember 19, 2023 | seekingalpha.comRhythm’s obesity therapy granted EU backing for orphan designationSeptember 19, 2023 | finance.yahoo.comCompanies Like Rhythm Pharmaceuticals (NASDAQ:RYTM) Are In A Position To Invest In GrowthSeptember 19, 2023 | finance.yahoo.comRhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic ObesitySeptember 24, 2023 | Behind the Markets (Ad)AI Creates New Cancer Drug - In Just 30 Days!On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...September 11, 2023 | finance.yahoo.comEVP Jennifer Lee Sells 6,166 Shares of Rhythm Pharmaceuticals Inc (RYTM)September 9, 2023 | mirror.co.ukHeadbangers: Rhythm Royale is far more than just another gimmicky pigeon gameSeptember 9, 2023 | msn.comBristol Rhythm & Roots Reunion kicks off with many returning music artistsSeptember 8, 2023 | finance.yahoo.comRhythm Pharmaceuticals Announces Update to September Conference ParticipationSeptember 6, 2023 | finanznachrichten.deRhythm Pharmaceuticals, Inc.: Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl SyndromeSeptember 6, 2023 | finance.yahoo.comRhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl SyndromeAugust 24, 2023 | sg.style.yahoo.comDirector Shun Nakamura’s ‘Samba de Amigo: Party Central’ Channels TikTok In Rhythm Game SequelAugust 22, 2023 | msn.comU.S. Air Force Rhythm in Blue Jazz Ensemble kicking off this week’s 8 Great TuesdaysAugust 7, 2023 | finance.yahoo.comRhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in FranceAugust 4, 2023 | seekingalpha.comRhythm Pharmaceuticals: A Virtual Monopoly In Orphan Obesity DisordersAugust 3, 2023 | msn.comMorgan Stanley Reiterates Rhythm Pharmaceuticals (RYTM) Equal-Weight RecommendationAugust 3, 2023 | msn.comB of A Securities Upgrades Rhythm Pharmaceuticals (RYTM)August 3, 2023 | finance.yahoo.comNeed To Know: Analysts Are Much More Bullish On Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) RevenuesAugust 2, 2023 | seekingalpha.comRhythm Pharmaceuticals: Growth, Uncertainty, And A 'Sell' RecommendationAugust 1, 2023 | marketwatch.comRhythm Pharmaceuticals Shares Jump After 2Q Revenue Tops ExpectationsAugust 1, 2023 | msn.comRhythm Pharma surges on strong Q2 sales; BofA upgradesAugust 1, 2023 | markets.businessinsider.comRhythm Pharmaceuticals (RYTM) Gets a Buy from Ladenburg Thalmann & Co.August 1, 2023 | finance.yahoo.comRhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business UpdateSee More Headlines Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RYTM Company Calendar Last Earnings8/01/2023Today9/23/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RYTM CUSIPN/A CIK1649904 Webwww.rhythmtx.com Phone(857) 264-4280Fax857-264-4299Employees177Year FoundedN/APrice Target and Rating Average Stock Price Forecast$37.17 High Stock Price Forecast$56.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+59.4%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-181,120,000.00 Net Margins-416.41% Pretax Margin-416.41% Return on Equity-76.93% Return on Assets-51.06% Debt Debt-to-Equity RatioN/A Current Ratio6.16 Quick Ratio6.02 Sales & Book Value Annual Sales$23.64 million Price / Sales56.11 Cash FlowN/A Price / Cash FlowN/A Book Value$4.69 per share Price / Book4.97Miscellaneous Outstanding Shares56,900,000Free Float54,228,000Market Cap$1.33 billion OptionableOptionable Beta1.62 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. David P. Meeker M.D. (Age 69)Chairman, Pres & CEO Comp: $1.17MMr. Hunter C. Smith M.B.A. (Age 54)CFO & Treasurer Comp: $692.2kMr. Joseph Shulman (Age 48)Chief Technical Officer Comp: $608.2kMr. Yann Mazabraud (Age 50)Exec. VP & Head of International Comp: $747.43kMs. Jennifer L. Chien (Age 48)Exec. VP & Head of North America Comp: $644.2kMr. Christopher German (Age 52)Corp. Controller, Principal Accounting Officer & Exec. Director Mr. David ConnollyHead of Investor Relations & Corp. CommunicationsMr. Jim FlahertySr. VP & Gen. CounselMs. Sarah RyanVP of Sales & MarketingMs. Pamela J. Cramer (Age 49)Chief HR Officer More ExecutivesKey CompetitorsAgios PharmaceuticalsNASDAQ:AGIOCatalyst PharmaceuticalsNASDAQ:CPRXIronwood PharmaceuticalsNASDAQ:IRWDStructure TherapeuticsNASDAQ:GPCRTG TherapeuticsNASDAQ:TGTXView All CompetitorsInsiders & InstitutionsBarclays PLCBought 43,110 shares on 9/21/2023Ownership: 0.229%Jennifer Kayden LeeSold 6,166 sharesTotal: $172,956.30 ($28.05/share)California State Teachers Retirement SystemBought 4,607 shares on 8/21/2023Ownership: 0.100%Nuveen Asset Management LLCBought 149,039 shares on 8/16/2023Ownership: 0.349%Citadel Advisors LLCSold 11,700 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions RYTM Stock - Frequently Asked Questions Should I buy or sell Rhythm Pharmaceuticals stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RYTM shares. View RYTM analyst ratings or view top-rated stocks. What is Rhythm Pharmaceuticals' stock price forecast for 2023? 6 analysts have issued 1-year target prices for Rhythm Pharmaceuticals' stock. Their RYTM share price forecasts range from $27.00 to $56.00. On average, they predict the company's stock price to reach $37.17 in the next year. This suggests a possible upside of 59.4% from the stock's current price. View analysts price targets for RYTM or view top-rated stocks among Wall Street analysts. How have RYTM shares performed in 2023? Rhythm Pharmaceuticals' stock was trading at $29.12 on January 1st, 2023. Since then, RYTM stock has decreased by 20.0% and is now trading at $23.31. View the best growth stocks for 2023 here. When is Rhythm Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our RYTM earnings forecast. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) issued its earnings results on Tuesday, August, 1st. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by $0.02. The firm earned $19.20 million during the quarter, compared to the consensus estimate of $15.03 million. Rhythm Pharmaceuticals had a negative net margin of 416.41% and a negative trailing twelve-month return on equity of 76.93%. The company's revenue was up 111.0% compared to the same quarter last year. During the same period last year, the business earned ($0.89) earnings per share. What ETFs hold Rhythm Pharmaceuticals' stock? ETFs with the largest weight of Rhythm Pharmaceuticals (NASDAQ:RYTM) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).BlackRock Future Health ETF (BMED). What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT). When did Rhythm Pharmaceuticals IPO? (RYTM) raised $100 million in an IPO on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager. What is Rhythm Pharmaceuticals' stock symbol? Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM." Who are Rhythm Pharmaceuticals' major shareholders? Rhythm Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.01%), RA Capital Management L.P. (9.98%), Goldman Sachs Group Inc. (9.11%), State Street Corp (5.74%), Polar Capital Holdings Plc (3.95%) and VR Adviser LLC (1.92%). Insiders that own company stock include David P Meeker, Hunter C Smith, Jennifer Chien, Jennifer Kayden Lee, Joseph Shulman, Pamela J Cramer, Ra Capital Management, LP, William T Roberts and Yann Mazabraud. View institutional ownership trends. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Rhythm Pharmaceuticals' stock price today? One share of RYTM stock can currently be purchased for approximately $23.31. How much money does Rhythm Pharmaceuticals make? Rhythm Pharmaceuticals (NASDAQ:RYTM) has a market capitalization of $1.33 billion and generates $23.64 million in revenue each year. The company earns $-181,120,000.00 in net income (profit) each year or ($3.28) on an earnings per share basis. How many employees does Rhythm Pharmaceuticals have? The company employs 177 workers across the globe. How can I contact Rhythm Pharmaceuticals? Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The official website for the company is www.rhythmtx.com. The company can be reached via phone at (857) 264-4280, via email at hannah.deresiewicz@sternir.com, or via fax at 857-264-4299. This page (NASDAQ:RYTM) was last updated on 9/24/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.